发明公开
EP2021507A2 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE
审中-公开
抑制PCSK9基因表达的组合物和方法
- 专利标题： COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE
- 专利标题（中）： 抑制PCSK9基因表达的组合物和方法
-
申请号： EP07762085.4申请日： 2007-05-14
-
公开(公告)号： EP2021507A2公开(公告)日： 2009-02-11
- 发明人: TAN, Pamela , BRAMLAGE, Birgit , FRANK-KAMENETSKY, Maria , FITZGERALD, Kevin , AKINC, Akin , KOTELIANSKI, Victor, E.
- 申请人： Alnylam Pharmaceuticals Inc.
- 申请人地址： 300 Third Street Cambridge, MA 02142 US
- 专利权人： Alnylam Pharmaceuticals Inc.
- 当前专利权人： Alnylam Pharmaceuticals Inc.
- 当前专利权人地址： 300 Third Street Cambridge, MA 02142 US
- 代理机构： Vossius & Partner
- 优先权： US799458P 20060511; US817203P 20060627; US840089P 20060825; US829914P 20061018; US901134P 20070213
- 国际公布： WO2007134161 20071122
- 主分类号： C12Q1/68
- IPC分类号： C12Q1/68 ; A01N43/04 ; C07H21/04 ; A61K31/07
摘要：
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a human PCSK9 gene in a cell, wherein said dsRNA comprises at least two sequences that are complementary to each other and wherein a sense strand comprises a first sequence and an antisense strand comprises a second sequence comprising a region of complementarity which is substantially complementary to at least a part of a mRNA encoding PCSK9, and wherein said region of complementarity is less than 30 nucleotides in length and wherein said dsRNA, upon contact with a cell expressing said PCSK9, inhibits expression of said PCSK9 gene, wherein (a) said first sequence is the sequence of SEQ ID NO: 1229 and said second sequence is the sequence of SEQ ID NO: 1230; (b) said first sequence is the sequence of SEQ ID NO: 1227 and said second sequence is the sequence of SEQ ID NO: 1228; or (c) said part of said mRNA encoding PCSK9 is the sequence from position 3530 to 3548 of the mRNA sequence of database entry NM_174936.
信息查询
